Desvenlafaxine Tablet, Extended Release
Product Images NDC 63304-191

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 63304-191). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Desvenlafaxine Str)

Chemical structure diagram of desvenlafaxine, the active ingredient in the extended-release tablets. The diagram shows the molecular structure with hydroxyl, methyl, and cyclohexane groups clearly illustrated.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A forest plot chart presenting geometric mean ratios (90% confidence intervals) for Cmax and AUC parameters of Desvenlafaxine in populations with varying degrees of renal and hepatic impairment and different demographic groups. The x-axis represents change relative to reference, with data points and error bars indicating variability across mild, moderate, severe renal and hepatic impairment, ESRD, gender, and age groups above 65 years.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A forest plot chart showing the geometric mean ratio with 90% confidence intervals for changes in pharmacokinetic parameters Cmax and AUC of desvenlafaxine when coadministered with the CYP3A4 inhibitor ketoconazole. The x-axis represents the change relative to a reference ranging from 0.5 to 2.0.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A forest plot chart depicting geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC) of drugs interacting with Desvenlafaxine at various doses. The chart compares changes relative to reference values for Desipramine, Midazolam, Tamoxifen, and Aripiprazole with Desvenlafaxine 50 mg, 100 mg, and 400 mg doses. Data points indicate whether the values are above, near, or below the reference line.*

FDA Label Image

Figure 4 (Desvenlafaxine Figur4)

A line graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares Desvenlafaxine Extended-Release Tablets 50 mg to placebo, with a solid line representing Desvenlafaxine and a dashed line representing placebo. The placebo group shows a higher proportion of relapse over time.*

FDA Label Image

Figure 5 (Desvenlafaxine Figur5)

A Kaplan-Meier survival curve graph showing the estimated proportion of patients with relapse (%) over time (days from randomization). Two lines compare Desvenlafaxine Extended-Release Tablets and placebo in terms of time to relapse in patients. The vertical axis represents the percentage of patients with relapse, and the horizontal axis represents days since randomization.*

FDA Label Image

Desvenlafaxine-50-mg.jpg (Desvenlafaxine 50 mg)

Desvenlafaxine extended-release tablets 50 mg in a blister pack label by Sun Pharmaceutical Industries, Inc. The label specifies 30 tablets and includes storage instructions, manufacturer and distributor information, and a barcode. It is marked for prescription use with a warning to dispense the accompanying medication guide.*

FDA Label Image

Desvenlafaxine-100-mg.jpg (Desvenlafaxine 100 mg)

Desvenlafaxine Extended-Release Tablets 100 mg packaging label showing dosage form as extended-release tablets with 30 tablets per package. Labeled for oral use, manufactured by Alembic Pharmaceuticals Limited and distributed by Sun Pharmaceutical Industries, Inc. Label includes storage instructions and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.